« Zurück
Startseite /
Necrostatin 2 (S enantiomer)

Necrostatin 2 (S enantiomer)

ArtNr	HY-14622B-50mg
Hersteller	MedChem Express
CAS-Nr.	852391-20-9
Menge	50 mg
Quantity options	10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Kategorie	Neuroscience Neuroinflammation Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.65
Citations	[1]Teng X, Keys H, Jeevanandam A, Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6836-40.\|[2]Jagtap PG, Degterev A, Choi S, Structure-activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007 Apr 19;50(8):1886-95.\|[3]Teng X, Degterev A, Jagtap P, Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5039-44.\|[4]Takahashi N, et al. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 2012 Nov 29;3:e437.
Smiles	O=C1N(C)C([C@H](CC2=CNC3=C2C=CC=C3Cl)N1)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	852391-20-9
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	RIP kinase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	277.711
Product Description	Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2. Necrostatin 2 is a potent necroptosis inhibitor, acts as a RIPK1 inhibitor lacking the IDO-targeting effect. Target: RIPK1 [4]Necrostatin 2 is a potent in vitro necroptosis inhibitors (exemplified by 1, EC50-0.05 uM) that also were efficacious in an animal model of ischemic stroke. Many Necroptosis inhibitor derivatives are designed for researchers.Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling necrosis. It can be induced in a FADD-deficient variant of human Jurkat T cells treated with TNF-a. 5-(1H-Indol-3-ylmethyl)-2-thiohydantoins and 5-(1H-indol-3-ylmethyl)hydantoins were found to be potent necroptosis inhibitors (called necrostatins).
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis
Isoform	RIPK1
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-14622B-50mg-safety-datasheet.pdf